Around the world over thousands of years, patients have received root-cause holistic treatment for their diseases with personalized
treatment, diet and lifestyle modification recommendations. Read the inspiring true stories of practitioners who heal people and who recovered
from their problems after obesity treatment at their clinics. Many have been generous to share their knowledge and experience for the benefit
of other holistic experts and patients alike. Many practitioners share their Case Studies and the healing powers of obesity and related therapies
as they heal people who benefited from our expertise.
Concept Of Balanced Ahara In Obesity
May 2018
/ onclick=”MoreLine(‘16317’, ‘Concept Of Balanced Ahara In Obesity’)”>
…more
/>wjpps, Volume 7, Issue 5, 1791-1796
Purple Sweet Potato Leaf Extract Induces Apoptosis and Reduces Inflammatory Adipokine Expression in 3T3-L1 Differentiated Adipocytes.
December 2014
/ onclick=”MoreLine(‘11641’, ‘Purple Sweet Potato Leaf Extract Induces Apoptosis and Reduces Inflammatory Adipokine Expression in 3T3-L1 Differentiated Adipocytes.’)”>
…more
/>Evid Based Complement Alternat Med. 2015 ;2015:126302. Epub 2015 Jun 11. PMID: 26170870
The effects of resveratrol intervention on risk markers of cardiovascular health in overweight and obese subjects: a pooled analysis of randomized controlled trials.
July 2016
Potential effects of resveratrol consumption on cardiovascular risk factors and body weight in overweight/obese adults have not been fully elucidated. Our present analysis was to evaluate the effects of resveratrol consumption on risk markers related to cardiovascular health in overweight/obese Individuals.
METHODS:
Multiple literature databases were systematically searched, and 21 studies were included. Effect sizes were expressed as weighted mean difference (WMD) and 95% confidence interval (CI), and heterogeneity was assessed with the I2 test. Publication bias and subgroup analyses were also performed.
Results:
There were variations in reporting quality of included studies. Resveratrol intervention significantly lowered total cholesterol (WMD, -0.19 mmol/L; 95% CI, -0.32 to -0.06; P = 0.004), systolic blood pressure (WMD, -2.26 mmHg; 95% CI, -4.82 to -0.49; P = 0.02), and fasting glucose (WMD, -0.22 mmol/L; 95% CI, -0.42 to -0.03; P = 0.03). Heterogeneity was noted for these outcomes (35.6%, 38.7% and 71.4%, respectively). Our subgroup analysis showed significant reductions in total cholesterol, systolic blood pressure, diastolic blood pressure, glucose, and insulin in subjects ingesting higher dose of resveratrol (?300 mg/day).
Conclusion:
Our finding provides evidence that daily resveratrol consumption might be a candidate as an adjunct to pharmacological management to better prevent and control cardiovascular in overweight/obese individuals.
/ onclick=”MoreLine(‘11531’, ‘The effects of resveratrol intervention on risk markers of cardiovascular health in overweight and obese subjects: a pooled analysis of randomized controlled trials.’)”>
…more
/>Obes Rev. 2016 Jul 26. Epub 2016 Jul 26. PMID: 27456934
Fucoidan, a sulfated polysaccharide, inhibits adipogenesis through the mitogen-activated protein kinase pathway in 3T3-L1 preadipocytes.
May 2010
METHODS:
Differentiation of 3T3-L1 preadipocytes was induced in the presence or absence of fucoidan. The effects of fucoidan on adipogenic gene expression and MAPK activation were investigated. KEY FINDINGS: Fucoidan treatment inhibits adipocyte differentiation, evidenced by decreased lipid accumulation and down regulation of adipocyte markers. Fucoidan then inhibited the expression of both early CCAAT-enhancer-binding proteins alpha (C/EBPalpha) and peroxisome proliferator-activated receptors gamma (PPARgamma) and late activating protein 2 (aP2) adipogenic transcription factors, which is a crucial role for adipocyte development. Moreover, our results revealed that fucoidan inhibited the early activation of p38 MAPKs, extracellular signal-regulated kinases (ERK) and Jun N-terminal kinase (JNK). SIGNIFICANCE: Overall, these findings are a strong indication that fucoidan might inhibit adipogenesis in 3T3-L1 preadipocytes, due to inhibition of the MAPK signaling pathway that involves adipogenic transcription factors.
/ onclick=”MoreLine(‘10984’, ‘Fucoidan, a sulfated polysaccharide, inhibits adipogenesis through the mitogen-activated protein kinase pathway in 3T3-L1 preadipocytes.’)”>
…more
/>Life Sci. 2010 May 22 ;86(21-22):791-7. Epub 2010 Mar 25. PMID: 20346961
Urinary bisphenol A and obesity NHANES 2003-2006
August 2011
Bisphenol A (BPA) is a chemical suspected of causing endocrine and metabolic disruption in animals and humans. In rodents, in utero exposure to low-dose BPA is associated with weight gain. Detectable levels of BPA are found in most Americans due to its widespread use in the manufacture of food and drink packaging. We hypothesized that urinary BPA concentrations would be positively associated with general and central obesity.
METHODS:
Cross-sectional analysis of urinary BPA concentrations, body mass index, and waist circumference in 2747 adults (aged 18-74), using pooled data from the 2003/04 and 2005/06 National Health and diet therapy Examination Surveys.
Results:
The creatinine-adjusted geometric mean urinary BPA concentration was 2.05?g/g creatinine (25th percentile: 1.18, 75% percentile: 3.33). Relative to those in the lowest BPA quartile, participants in the upper BPA quartiles were more likely to be classified as obese (quartile 2 odds ratio (OR): 1.85, 95% confidence interval (CI): 1.22, 2.79; quartile 3 OR: 1.60, 95% CI: 1.05-2.44; quartile 4 OR: 1.76, 95% CI: 1.06-2.94). Higher BPA concentration was also associated with abdominal obesity (quartile 2 OR: 1.62, 95% CI: 1.11, 2.36; quartile 3 OR: 1.39, 95% CI: 1.02-1.90; quartile 4 OR: 1.58, 95% CI: 1.03-2.42). CONCLUSIONS: Higher BPA exposure is associated with general and central obesity in the general adult population of the United States. Reverse causation is of concern due to the cross-sectional nature of this study; longitudinal studies are needed to clarify the direction of the association.
/ onclick=”MoreLine(‘10951’, ‘Urinary bisphenol A and obesity NHANES 2003-2006’)”>
…more
/>Environ Res. 2011 Aug ;111(6):825-30. Epub 2011 Jun 14. PMID: 21676388
Association between urinary bisphenol A concentration and obesity prevalence in children and adolescents.
September 2012
To examine associations between urinary BPA concentration and body mass outcomes in children. DESIGN, SETTING, AND PARTICIPANTS: Cross-sectional analysis of a nationally representative subsample of 2838 participants aged 6 through 19 years randomly selected for measurement of urinary BPA concentration in the 2003-2008 National Health and diet therapy Examination Surveys. MAIN OUTCOME MEASURES: Body mass index (BMI), converted to sex- and age-standardized z scores and used to classify participants as overweight (BMI?85th percentile for age/sex) or obese (BMI ?95th percentile).
Results:
Median urinary BPA concentration was 2.8 ng/mL (interquartile range, 1.5-5.6). Of the participants, 1047 (34.1% [SE, 1.5%]) were overweight and 590 (17.8% [SE, 1.3%]) were obese. Controlling for race/ethnicity, age, caregiver education, poverty to income ratio, sex, serum cotinine level, caloric intake, television watching, and urinary creatinine level, children in the lowest urinary BPA quartile had a lower estimated prevalence of obesity (10.3% [95% CI, 7.5%-13.1%]) than those in quartiles 2 (20.1% [95% CI, 14.5%-25.6%]), 3 (19.0% [95% CI, 13.7%-24.2%]), and 4 (22.3% [95% CI, 16.6%-27.9%]). Similar patterns of association were found in multivariable analyses examining the association between quartiled urinary BPA concentration and BMI z score and in analyses that examined the logarithm of urinary BPA concentration and the prevalence of obesity. Obesity was not associated with exposure to other environmental phenols commonly used in other consumer products, such as sunscreens and soaps. In stratified analysis, significant associations between urinary BPA concentrations and obesity were found among whites (P
/ onclick=”MoreLine(‘10950’, ‘Association between urinary bisphenol A concentration and obesity prevalence in children and adolescents.’)”>
…more
/>JAMA. 2012 Sep 19 ;308(11):1113-21. PMID: 22990270